Cargando…
Imatinib Inhibits GH Secretion From Somatotropinomas
Background: Imatinib, a tyrosine kinase inhibitor, causes growth failure in children with chronic myeloid leukemia probably by targeting the growth hormone (GH)/insulin like growth factor-1 (IGF-1) axis. We aim to explore the imatinib targets expression in pituitary adenomas and study the effect of...
Autores principales: | Gupta, Prakamya, Rai, Ashutosh, Mukherjee, Kanchan Kumar, Sachdeva, Naresh, Radotra, Bishan Das, Punia, Raj Pal Singh, Vashista, Rakesh Kumar, Hota, Debasish, Srinivasan, Anand, Dhandapani, Sivashanmugam, Gupta, Sunil Kumar, Bhansali, Anil, Dutta, Pinaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120347/ https://www.ncbi.nlm.nih.gov/pubmed/30210447 http://dx.doi.org/10.3389/fendo.2018.00453 |
Ejemplares similares
-
The outcome of TSHoma from a tertiary care institute in India
por: Dutta, Aditya, et al.
Publicado: (2021) -
Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas
por: Rai, Ashutosh, et al.
Publicado: (2021) -
Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience
por: Dutta, Pinaki, et al.
Publicado: (2015) -
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
por: Das, Liza, et al.
Publicado: (2021) -
Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
por: Dutta, Pinaki, et al.
Publicado: (2019)